Effect of efavirenz treatment on the pharmacokinetics of nelfinavir boosted by ritonavir in healthy volunteers

British Journal of Clinical Pharmacology

Volumn 58, Issue 6, 2004, Pages 632-640

  La Porte, Charles J L ^a   De Graaff Teulen, M J A ^a   Colbers, E P H ^b   Voncken, D S ^b   Ibanez, S Marco ^c   Koopmans, P P ^a   Hekster, Y A ^a   Burger, D M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Farma Research BV   (Netherlands)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Efavirenz; Nelfinavir; Nucleoside sparing; Once daily; Pharmacokinetics; Ritonavir

Indexed keywords

DRUG METABOLITE; EFAVIRENZ; M 8; NELFINAVIR; NELFINAVIR HYDROXY TERT BUTYLAMIDE; RITONAVIR; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ADULT; AGITATION; ANOREXIA; AREA UNDER THE CURVE; AREA UNDER THE PLASMA CONCENTRATION TIME CURVE; ATTENTION DEFICIT DISORDER; BIOEQUIVALENCE; CHRONOPHARMACOLOGY; CIRCUMORAL PARESTHESIA; CLINICAL TRIAL; CONFERENCE PAPER; CONNECTIVE TISSUE DISEASE; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FEMALE; FLATULENCE; HEADACHE; HEAVINESS SENSATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHIDROSIS; INSOMNIA; LOOSE FECES; MALE; MAXIMUM PLASMA DRUG CONCENTRATION; MOUTH DISEASE; MULTIPLE DRUG DOSE; MYALGIA; NAUSEA; NORMAL HUMAN; OPEN STUDY; PARESTHESIA; PRIORITY JOURNAL; SIDE EFFECT; SOMNOLENCE; STOMATITIS; TIME TO REACH MAXIMUM PLASMA DRUG CONCENTRATION; UNPLEASANT DREAM;

DRUG COMBINATIONS; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; NELFINAVIR; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR;

EID: 10844260891     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02214.x     Document Type: Conference Paper

References (26)

1. Hogg RS, Heath KV, Yip B et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. J Am Ivied Assoc 1998; 279: 450-4.
2. Palella FJJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60.
3. Harrington M, Carpenter CC. Hit HIV-1 hard, but only when necessary. Lancet 2000; 355: 2147-52.
4. Paterson DL, Swindells S, Mohr J et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30.
5. Joly V, Descamps D, Yeni P. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens. AIDS Rev 2002; 4: 128-39.
6. Mehta S, Moore RD, Graham NMH. Potential factors affecting adherence with HIV therapy. AIDS 1997; 11: 1665-70.
7. Stone VE. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. Clin Infect Dis 2001; 33: 865-72.
8. Aarnoutse RE, Droste JA, Van Oosterhout JJ et al. Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers. Br J Clin Pharmacol 2003; 55: 115-25.
9. Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinetics 1998; 35: 275-91.
10. Bardsley-Elliot A, Plosker GL. Nelfinavir: an update on its use in HIV infection. Drugs 2000; 59: 581-620.
11. Zhang KE, Wu E, Patick AK et al. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. Antimicrobial Agents Chemother 2001; 45: 1086-93.
12. Lillibridge JH, Lee CA, Pithavala YK et al. The Role of Polymorphic CYP2C19 in the Metabolism of Nelfinavir Mesylate, 12th AAPS conference, 1998. Abstract 3035, 1998.
13. Flexner C. Steady-state Pharmacokinetic Interactions Between Ritonavir (RTV), Nelfinavir (NFV) and the Nelfinavir Active Metabolite M8 (AG1402), 12th World Aids Conference, 28, Geneva, Switzerland. Abstract 42265, 2002.
14. Kurowski M, Kaeser B, Sawyer A, Popescu M, Mrozikiewicz A. Low-dose ritonavir moderately enhances nelfinavir exposure. Clin Pharmacol Therapeutics 2002; 72: 123-32.
15. Merck Sharp & Dohme Limited. Stocrin®. Summary of Product Characteristics. Merck Sharp & Dohme Ltd, Hoddesdon, UK, 2002.
16. Roche Registration Ltd. Viracept®. Summary of Product Characteristics. Roche Registration Ltd, Welwyn Garden City, UK, 2001.
17. Droste JAH, Verweij-van Wissen CPWCM, Burger DM. Simultaneous determination of the HIV drugs Indinavir, Amprenavir, Saquinavir, Ritonavir, Lopinavir, Nelfinavir, the Nelfinavir hydroxymetabolite M8 and Nevirapine in Human Plasma by Reversed Phase High Performance Liquid Chromatography. Therapeutic Drug Monitoring 2003; 25: 393-9.
18. Aarnoutse RE, Crintjes KJ, Telgt DS et al. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clin Pharmacol Therapeutics 2002; 71: 57-67.
19. Williams RL, Chen ML, Hauck WW. Equivalence approaches. Clin Pharmacol Therapeutics 2002; 72: 229-37.
20. Fiske WD, Benedek IH, White SJ, Pepperess KA, Joseph JL, Komhauser DM. Pharmacokinetic Interaction between Efavirenz (EFV) and Nelfinavir Mesylate (NFV) in Healthy Volunteers, 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1998. Abstract 349, 1998; 1-2.
21. Smith PF, Robbins G, Shafer R et al. and ACTG 384 Study Team. Effect of Efavirenz on the Pharmacokinetics of Nelfinavir and M8 in Naive, HIV-infected Patients Receiving Long-term HAART Therapy, 10th Conference on Retroviruses and Opportunistic Infections, Boston, 2003, Abstract 148, 2003.
22. Anonymous. Optimising TDM in HIV clinical care. A practical guide to performing therapeutic drug monitoring (TDM) for antiretroviral agents. Available: http://www.HIVpharmacology.com Last accessed 18 June 2004.
23. Baede-van Dijk PA, Hugen PWH, Verwey-van Wissen CPWGM, Koopmans PP, Burger DM, Hekster YA. Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients. AIDS 2001; 15: 991-8.
24. Fiske WD, Benedek IH, Joseph JL et al. Pharmacokinetics of Efavirenz (EFV) and Ritonavir (RIT) after Multiple Oral Doses in Healthy Volunteers. 12th World Aids Conference 28, Geneva, Switzerland. Abstract 42269, 1998.
25. Smith PF, DiCenzo R, Morse GD. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinetics 2001; 40: 893-905.
26. Villani P, Regazzi MB, Castelli F et al. Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients. Br J Clin Pharmacol 1999; 48: 712-15.